Search

everythinglearnresearchcommunity

for

Search:↓

Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.

The conversation is about using a topical serum for hair loss with ingredients like finasteride and minoxidil, and the option to exclude retinoic acid and hydrocortisone due to concerns about long-term effects. One user prefers using only finasteride, avoiding minoxidil and retinoic acid, and plans to remove hydrocortisone in future orders.

Hair cloning is discussed, focusing on its current status and potential availability. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation humorously acknowledges the role of mice in testing Minoxidil for hair loss while also discussing the ethics of animal testing. Some users argue against animal testing, citing cruelty, while others defend its necessity for medical advancements.

Hair transplant recipients are concerned about whether dormant follicles are permanently damaged by incisions, but some believe undamaged follicles could still regrow if a treatment like PP405 is effective. Opinions vary on the impact of transplants on original follicles, with some suggesting treatments like finasteride can help regrow hair.

A user with seborrheic dermatitis is experiencing bald spots and hair thinning despite changing their diet and taking oral minoxidil. Another user suggests using ketoconazole shampoo properly, using a scalp massager, applying rosemary/peppermint oil, keeping hair short, and taking fish oil to improve scalp health.

GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

Biotin supplements are considered ineffective for hair loss and are not supported by evidence. People in the conversation have mixed experiences, with some noting benefits for nails and skin but not hair, while others continue to use biotin as part of their vitamin regimen.

A user had a hair transplant 16 years ago and lost hair after stopping finasteride. They're now using a combination of treatments including oral dutasteride, topical and oral minoxidil, Pyrilutamide, and microneedling, and have seen improved density but are unsure if it's enough to grow their hair out. They also had a bad experience with scalp micropigmentation (SMP) and are considering redoing it.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

A user is concerned about hair loss and acne from a one-week course of 70 mg/day oral prednisolone for severe tinnitus. They are asking if these side effects are common.

The post discusses the theory that persistent dandruff in areas prone to hair loss could be a sign of hair follicles dying due to DHT, indicating balding. The responses vary, with some users noting improvements in dandruff and hair loss with treatments like Dutasteride, while others experienced hair loss without dandruff.

The user is frustrated with ongoing hair loss despite using oral finasteride and topical minoxidil. They are considering adding magnesium to their diet and exploring other treatments like micro-needling and keto shampoo.

The conversation humorously suggests using immunosuppressants like ciclosporine and oral minoxidil for hair regrowth, with a satirical plan involving hair transplants from family members. It highlights the side effects and impracticality of such treatments, emphasizing the post's satirical nature.

Verteporfin and BPC-157 are being discussed as potential treatments for hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841.

The user reports significant hair regrowth using a topical solution of 5% minoxidil and 0.1% finasteride twice daily, along with derma rolling twice a week. They have not experienced shedding and are optimistic about continued hair growth.

Latanoprost/bimatoprost's effectiveness in hair loss treatment is discussed, with its potential to convert vellus hairs to terminal hairs. It works differently from minoxidil and finasteride, and may be best for hairline application, but is not a replacement for them due to price and mechanism.

A 37-year-old male resolved scalp folliculitis by adopting a low-histamine diet and taking Vitamin A, Zinc, and Fish Oil, leading to better skin health and thicker hair. He warns about the potential toxicity of excessive Vitamin A intake.

Age-linked hair loss is linked to disappearing collagen. Treatments discussed include minoxidil, finasteride, RU58841, tretinoin, microneedling, and collagen supplements.

The user has been using a combination of finasteride/dutasteride, minoxidil, tretinoin, and hydrocortisone with microneedling and ketoconazole shampoo for hair loss. They are asking if the baby hairs growing will turn into terminal hairs with continued treatment.

Verteporfin human clinical trials for hair loss may start in 2025. Additional resources and presentations are available for more information.

A clinical trial for hair loss treatments involving Minoxidil, Finasteride, and RU58841, and when the results of the trial will be available.

Clascoterone (Breezula) showed positive results for treating hair loss without affecting cortisol levels. Opinions vary, with some users optimistic about its potential and others critical of its effectiveness compared to existing treatments like finasteride.

The user is using a combination of finasteride, dutasteride, oral and topical minoxidil, PRP, and stem cell treatments for hair loss. They report slowed shedding and new vellus hairs on the hairline, questioning if they are a strong responder to the treatment.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

The conversation discusses a user's plan to inject NAD+ and GHK-Cu into their scalp to improve hair health, with concerns raised about the risks of infection and necrosis. Alternatives like finasteride, dutasteride, microneedling, oral minoxidil, and scalp massages are suggested.

The user is experiencing stage 2 hair loss and thinning, noticing more scalp visibility with short hair. They are considering diet, yoga, scalp massage, supplements, and a serum recommended by their doctor, and questioning if it's safe to stop using the serum and whether to get a blood test since hair loss isn't a family trait.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

3aHSD enzyme's role in hair loss and a crowdfund for research. Goal: explore new treatments, study RU58841, and develop natural topical product.